THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The data are part of a presentation at the annual meeting of European League Against Rheumatism being held this week in Lisbon, Portugal.
"A significant number of patients treated with ENBREL in this study saw a marked improvement in as early as two weeks after initiation of treatment. Patients reached maximum relief within the first two months of the study and experienced sustained results for the remainder of the six-month study," said Dr. John Davis, assistant professor of medicine at the University of California-San Francisco and associate director of the Department of Medicine Clinical Trials Center. "I am excited about these encouraging results with ENBREL, especially since it is the first treatment to show improvement in AS patients' range of spinal motion in a phase 3 study."
The multi-center, double-blind, placebo-controlled study randomized 277 patients to receive either ENBREL (25 mg twice weekly; n=138) or placebo (n=139) over a 6-month period. The primary endpoint of the pivotal Phase 3 study was the percentage of patients at 12 weeks and 24 weeks achieving a 20 percent improvement in the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20), a composite measure that includes back pain, inflammation and physical function.
At week 12, 60 percent of patients treated with ENBREL achieved the ASAS 20 compared with 27 percent of patients in the placebo group. At 24 weeks, 58 percent of patients treated with ENBREL achieved the ASAS 20 compared with 23 percent of the placebo patiPage: 1 2 3 4 Related biology news :1
Contact: Rebecca Hamm, Amgen
. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study2
. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function3
. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief4
. ENBREL is first therapy approved for psoriatic arthritis5
. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)6
. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting7
. Rare mutations can significantly increase risk factor for heart disease8
. Cancer health risk significantly underestimated by EPAs ambient model estimates9
. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk10
. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma11
. Cognitive abilities increase significantly with time in most prematurely born children